Zirabev was also approved for use in the European Union in February 2019 for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable
advanced, metastatic or recurrent NSCLC, advanced and/or metastatic RCC and persistent, recurrent or metastatic carcinoma of the cervix.
These latest results show a durable and sustained OS benefit in patients with unresectable
, Stage III NSCLC who had not progressed following concurrent chemoradiation therapy (CRT), a previous standard-of-care (SoC) treatment.
These latest results reveal a durable and sustained overall survival benefit in patients with unresectable
, Stage III non-small cell lung cancer who had not progressed following concurrent chemoradiation therapy, a previous standard-of-care treatment.
Dave Fredrickson, executive vice president of Oncology at Astra, said: "Our data for Lynparza in BRCA-mutated metastatic pancreatic cancer and for Imfinzi in unresectable
stage three non-small cell lung cancer illustrate our ambition to change medical practice for better patient outcomes."
In China, LENVIMA was approved first as a single agent for the treatment of patients with unresectable
hepatocellular carcinoma (HCC) who have not received prior systemic therapy in September 2018.
According to the company, these data establish Imfinzi as the first immunotherapy to demonstrate an overall survival benefit for patients with unresectable
, stage III non-small cell lung cancer following chemoradiation therapy.
We present a case of a patient with a locally advanced, initially unresectable
PDAC of the body and tail, who underwent neoadjuvant chemoradiation, with prolonged chemotherapy, followed by R0 radical resection that included subtotal pancreatectomy, splenectomy, and left adrenalectomy with no residual tumor identified in the pathologic specimen.
Currently, in a substantial number of patients initially diagnosed with unresectable
Pembrolizumab was first approved in 2014 for the treatment of patients with unresectable
or metastatic melanoma and disease progression following ipilimumab and, if the patients were positive for the BRAF V600 mutation, a BRAF inhibitor.
Dabrafenib and trametinib are the third and fourth drugs to be approved by the FDA for metastatic or unresectable
melanoma since 2011, when vemurafenib (Zelboraf) and ipilimumab (Yervoy) were approved.
Given the demonstrated benefit of adding chemotherapy to radiotherapy, concomitant CRT is currently the standard of care for people with unresectable
HNCs, provided no contraindication towards such aggressive management of the disease exists.
The trial is evaluating Zymafos, or palifosfamide, as a treatment for patients with unresectable
or metastatic soft-tissue sarcoma.